← Oncology Approval Tracker

FDA DECISION ·

Nerlynx

neratinib · Puma Biotechnology

FDA approvalNew dosing regimenBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds the option to start with a lower daily dose and escalate over the first two weeks before the full daily dose in existing HER2-positive breast cancer uses.

LAMPGEN ANALYSIS

Why it matters

The label incorporates a dosing option studied to improve management of neratinib-associated diarrhea.

What research teams should watch

Build the staged doses into dispensing and capture diarrhea, supportive treatment and whether escalation was completed.

PRIMARY RECORDS

Sources